Lipocine Inc (LPCN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY, X1 84108

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the U.S. Food and Drug Administration (the 'FDA') for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadi® in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a Phase 2 clinical evaluation when administered once daily or twice daily, TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA.

Data as of 2021-05-08 11:15:11 -0400
Market Cap122.724 Million Shares Outstanding88.291 Million Avg 30-day Volume911.083 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-5.67 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.3785 52-week High/Low2.42 / 0.675 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from LPCN instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 34 30 13.33% 8 (0.48%) 8 (0.5%) 0.0%
13F shares: 8.446 Million 7.139 Million 18.3% 934.32 Thousand 878.129 Thousand 6.4%
% Ownership 12.8576 10.8688 18.3% 1.4224 1.3369 6.4%
New Positions: 10 6 66.67% 3 3 0.0%
Increased Positions 10 11 -9.09% 4 4 0.0%
Closed Positions 6 10 -40.0% 3 3 0.0%
Reduced Positions 3 3 0.0% 1
Total Calls 466.565 Thousand 544.266 Thousand -14.28% 68.2 Thousand 55.841 Thousand 22.13%
Total Puts 14.425 Thousand 100.894 Thousand -85.7% 0 150 -100.0%
PUT/CALL Ratio 0.03 0.19 -84.21% 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding LPCN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LPCN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PATEL MAHESH V. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2021-01-04 4

HIGUCHI JOHN W.

  • Director
693,548 2020-12-31 3

FINK JEFFREY ARVIN

  • Director
6,562 2020-12-16 2

ONO RICHARD DANA

  • Director
10,125 2020-12-16 2

HILL STEPHEN A

  • Director
12,750 2020-12-16 2

BROWN MORGAN R EVP AND CFO

  • Officer
194,504 2020-12-15 2

BASS GREGORY BROOKS CHIEF COMMERCIAL OFFICER

  • Officer
5,625 2017-12-29 0

MATTILA JYRKI CHIEF BUSINESS OFFICER

  • Officer
0 2017-01-26 0

VENKATESHWARAN SRINIVASAN VP RANDD

  • Officer
0 2014-08-14 0

SIMMONS GERALD T CHIEF BUSINESS OFFICER

  • Officer
0 2014-08-14 0

MERRELL ROBERT K. VP FINANCE

  • Officer
No longer subject to file 2013-12-10 0

VISIUM BALANCED MASTER FUND, LTD.

  • 10% Owner
1,206,000 2013-07-26 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
LIPOCINE INC LPCN 2021-05-11 22:15:03 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 21:45:03 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 21:15:03 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 20:45:03 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 20:15:03 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 19:45:03 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 19:15:02 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 18:45:02 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 18:15:03 UTC -4.7536 4.8036 500000
LIPOCINE INC LPCN 2021-05-11 17:45:03 UTC -4.7536 4.8036 500000
LIPOCINE INC LPCN 2021-05-11 17:15:04 UTC -4.7536 4.8036 500000
LIPOCINE INC LPCN 2021-05-11 16:45:04 UTC -4.8739 4.9239 500000
LIPOCINE INC LPCN 2021-05-11 16:15:04 UTC -4.8739 4.9239 500000
LIPOCINE INC LPCN 2021-05-11 15:45:03 UTC -4.8739 4.9239 500000
LIPOCINE INC LPCN 2021-05-11 15:15:03 UTC -4.8739 4.9239 500000
LIPOCINE INC LPCN 2021-05-11 14:45:03 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 14:15:03 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 13:45:04 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 13:15:04 UTC -4.7536 4.8036 600000
LIPOCINE INC LPCN 2021-05-11 12:45:03 UTC -4.7536 4.8036 250000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments